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Abstract
Objective-To define the concentrations ofinhibin in serum and tissue of patients with hydatidiform mole and assess their value as a clinical marker ofthe condition.
Design-Prospective study of new patients with hydatidiform mole, comparison of paired observations, and case-control analysis.
Setting-A university hospital, two large public hospitals, and a private women's clinic in Japan.
Patients-Seven consecutive referred patients seen over four months with newly diagnosed complete hydatidiform mole, including one in whom the mole was accompanied by viable twin fetuses (case excluded from statistical analysis because of unique clinical features). All patients followed up for six months after evacuation of molar tissue.
End point-Correlation of serum inhibin concentrations with trophoblastic disease.
Measurements and main results-Serum concentrations of inhibin, human chorionic gonadotrophin, and follicle stimulating hormone were compared before and seven to 10 days after evacuation of the mole. Before evacuation the serum inhibin concentrations (median 8*3 U/ml; 95% confidence interval 2-4 to 34.5) were significantly greater than in 21 normal women at the same stage of pregnancy (2.8 U/ml; 2*1 to 3.6), and inhibin in molar tissue was also present in high concentrations (578 U/mI cytosol; 158 to 1162). Seven to 10 days after evacuation inhibin concentrations in serum samples from the same patients declined significantly to values (0 4 U/mI; 0-1 to 1-4) similar to those seen in the follicular phase of normal menstrual cycles. None of the four patients whose serum inhibin concentrations were 0 4 U/mI or less after evacuation developed persistent trophoblastic disease. Though serum human chorionic gonadotrophin concentrations declined after evacuation (6-6x 103 IU/l; 0-8x
Introduction
Inhibin, a glycoprotein hormone produced by the testis and ovary, has the ability preferentially to suppress the secretion of follicle stimulating hormone by the pituitary. After its initial isolation from bovine follicular fluid' we showed that inhibin was also produced by the placenta2 and that concentrations rose during early pregnancy.3 Other studies using immunocytochemistry have localised inhibin to the cytotrophoblast of the placenta,4 which has been shown to contain messenger ribonucleic acid for the inhibin subunits.5 The production of inhibin by trophoblastic tissue and the availability of specific radioimmunoassays for inhibin prompted us to study the concentrations of inhibin in women with a gestational trophoblastic disease such as hydatidiform mole. This paper reports our results.
Subjects and methods
Serum and molar tissue were obtained from seven patients (median age 32 years, range 18-46) with hydatidiform mole managed at Tohoku University Hospital and its affiliated institutions. Diagnosis was based on the clinical symptoms, ultrasonic findings, laboratory data, and histological appearances of samples obtained at curettage. Gestational age at the time of primary evacuation was calculated from the date of the last menstrual period as a median of 12-1 weeks (range 9-17 weeks), and no patient had a previous history of gestational trophoblastic disease. All except one of the cases were diagnosed as complete hydatidiform mole without a fetus. In the exception (case 1) the hydatidiform mole coexisted with viable twin fetuses. This patient had been treated with human menopausal and human chorionic gonadotrophin for anovulation. Two months after diagnosis of the mole and despite prophylactic methotrexate one week after primary evacuation the patient had persistent trophoblastic disease. in this case it was excluded from statistical analysis. A second patient (case 2) was also given methotrexate prophylactically, beginning two days after primary evacuation on the basis of clinical judgment about her gestational age (17 weeks). The other five patients were not given prophylaxis. During six months of follow up three patients (cases 1, 3, and 4) were diagnosed as having persistent trophoblastic disease and given intensive chemotherapy. Blood samples were taken both on the day of primary evacuation and seven to 10 days thereafter. In case 2 the second sample was taken 10 days after curettage and four days after the finish of initial prophylactic chemotherapy. Molar tissue was washed extensively to remove macroscopic blood clots, homogenised without the addition of buffer, sonicated, and centrifuged at 150 000 g for 35 minutes. Serum samples from 21 normal women with pregnancies of six to 18 n weeks served as controls.
Inhibin was measured by a specific radioimmunoassay67 using an antiserum that had been raised to inhibin fractions of increasing purity obtained during L the purification of bovine 31 kD inhibin and used with iodinated bovine 31 kD inhibin as the tracer. The ns standard consisted of a pool of serum from women receiving ovarian hyperstimulation for in vitro ferse tilisation and which had been assayed against a previously characterised bioassay standard.7 The cross is reactivity of activin A transforming growth factor , mullerian inhibiting substance, and related protein 'd hormones was less than 0 5% in the radioimmunoassay.
Concentrations 2) . In serum samples taken before evacuation inhibin concentrations correlated with human chorionic gonadotrophin values (Spearman rank correlation coefficient r=0-89; p<005). Though serum inhibin concentrations declined dramatically within 10 days after evacuation, serum follicle stimulating hormone concentrations were unchanged (median before evacuation 5 0 IU/1, 95% confidence interval 4-0 to 5 5; median after evacuation 6-0 IU/1, 1-4 to 7 5). Molar tissue contained exceptionally high concentrations of inhibin (578 U/ml cytosol; 158 to 1162). The patient in case 1 showed a similar pattern in all hormone concentrations studied with the exception of a high concentration of inhibin after evacuation (4 3 U/ ml). In the other two patients who developed persistent trophoblastic disease serum inhibin concentrations after evacuation were 1-4 U/ml (case 3) and 0 9 U/mI (case 4). All four patients who remained free of persistent trophoblastic disease had serum inhibin concentrations of 0 4 U/mI or less after evacuation.
Discussion
This study shows that serum inhibin concentrations are substantially increased in patients with hydatidiform mole and may provide an important diagnostic marker of the condition. The findings are consistent with the localisation of inhibin to the cytotrophoblast of normal placenta. 4 The exceptionally high concentrations of inhibin in molar tissue and the dramatic fall in concentrations in the serum after evacuation strongly support the mole as the source of the circulating inhibin. Interestingly concentrations of inhibin and human chorionic gonadotrophin were closely correlated in pretreatment serum samples. Concentrations of human chorionic gonadotrophin, however, do not have a high diagnostic value for hydatidiform mole as values in this condition show considerable overlap with those in normal pregnancy.89 On the other hand, the pre-evacuation serum inhibin concentrations in all but one patient, whose pregnancy was comparatively advanced (case 2), were higher than the 95% confidence interval of values in 21 normal women whose pregnancies were at a similar stage (fig 1) . Further study is required to define normal inhibin concentrations in larger numbers of women in each gestational period.
Our results also suggest that serum inhibin measurements may be of value in deciding which women may be at increased risk of developing persistent trophoblastic disease, including invasive moles and choriocarcinoma. Up to now the persistence of raised human chorionic gonadotrophin concentrations after evacuation of hydatidiform mole has been used to identify patients thought to be at increased risk.9' The regression curve of serum human chorionic gonadotrophin concentrations after the evacuation of a hydatidiform mole, however, shows that it takes about 10 weeks for values to reach the non-pregnant level." Furthermore, distinguishing patients with spontaneous remission from those with persistent trophoblastic disease can be achieved only some six weeks after evacuation of the mole," so that it usually takes at least four to six weeks before chemotherapy can be started in those patients with persistent trophoblastic disease.
By contrast, the decline of serum inhibin concentrations to non-pregnant values is much more rapid, and in all our patients who did not develop persistent trophoblastic disease concentrations reached those of the early follicular phase within 10 days. Hence persistently raised inhibin concentrations one to two weeks after evacuation of a mole may provide an early indication of persistent trophoblastic disease. This is supported by the finding of postevacuation inhibin concentrations higher than those found in the early follicular phase in cases 1, 3, and 4. These three patients showed an abnormal decline in human chorionic gonadotrophin concentrations and required chemotherapy. Our data strongly suggest that the measurement of inhibin concentrations will be of value in the management of trophoblastic disease, and we believe that further data should be collected to evaluate the concept.
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